Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch

Primary Objective

• To evaluate the efficacy of aripiprazole long acting injectable form in Turkish patients with schizophrenia on psychosocial functioning, quality of life and patient reported acceptability of treatment. Secondary Objective(s)
• To evaluate the cognitive functioning of the patients
• To evaluate positive and negative symptoms of the Aripiprazole Long Acting Injectable (LAI),
• To evaluate adherence of Aripiprazole Long Acting Injectable (LAI) treatment,
• To evaluate tolerability of Aripiprazole Long Acting Injectable (LAI).

• Inclusion Criteria:

• Participants 18-45 of years age fulfilling DSM-IV-TR diagnostic criteria of schizophrenia,
• Disease history of ≤ 3 years (≤ 3 years after the emergence of first psychotic symptoms),
• A history of symptom exacerbation or relapse when not receiving antipsychotics therefore requiring maintenance antipsychotic treatment,
• Informed written consent,
• Not on any antipsychotic treatment at least for 3 months or requiring a switch in treatment for any reason (lack of efficacy/ inadequate response to current antipsychotic(s), intolerance, nonadherence), and with the potential to benefit from extended treatment with an LAI formulation, in the investigator's opinion.
• Lack of efficacy is defined as subjects with a baseline total PANSS score ≥70 or ≥2 items scoring ≥4 in the Positive or Negative Symptom Subscale
• Lack of tolerability is defined as the presence of clinically relevant side effects with the previous antipsychotic medication.
• Being literate in order to be able to answer the self report scales.
• Exclusion Criteria:

• DSM-IV-TR diagnosis other than schizophrenia or experiencing acute depressive symptoms in the past 30 days requiring ADT depending on the clinical decision of the investigator.
• Antipsychotic resistant or refractory schizophrenia
• A history of failure to clozapine treatment or response to clozapine treatment only.
• Significant risk of violent behavior or risk of self-harm
• Currently meets DSM-IV-TR criteria for alcohol and substance dependence
• Any clinically significant medical or neurological disorder
• Any medically significant abnormal laboratory test or ECG result at screening
• Pregnant, lactating.